The GLP-1 weight loss drug market just got a fourth major player. Foundayo — the triple-receptor agonist that the FDA approved on April 1, 2026 — is now competing directly against Ozempic, Wegovy, and Mounjaro. With more options than ever, patients and doctors are asking the same question: which drug actually delivers the best results, at what cost, and for whom?
This guide cuts through the noise with a head-to-head breakdown of all four drugs across the metrics that matter most: average weight loss, monthly cost, speed to results, insurance coverage, and side effect profiles.
What Are These Drugs and How Do They Work?
Ozempic (semaglutide, 0.5–2mg) was the first of this generation to gain wide use. Approved by the FDA for type 2 diabetes in 2017, it works by mimicking the GLP-1 hormone — slowing digestion, increasing insulin secretion, and reducing appetite. It's still prescribed off-label for weight loss despite not being officially approved for that purpose in its Ozempic form.
Wegovy is the same drug — semaglutide — but at a higher dose (2.4mg weekly), specifically FDA-approved for chronic weight management in adults with a BMI of 30+ or 27+ with a weight-related condition. It's made by the same company (Novo Nordisk) and represents the "official" weight-loss version of Ozempic.
Mounjaro (tirzepatide) changed the game when Eli Lilly introduced dual-receptor action. Unlike pure GLP-1 agonists, tirzepatide targets both GLP-1 and GIP receptors simultaneously. The combined signal produces stronger appetite suppression and better blood sugar control than semaglutide alone. Mounjaro is approved for type 2 diabetes; its weight-loss twin Zepbound carries the obesity indication.
Foundayo is the newest entrant — a triple agonist that targets GLP-1, GIP, and glucagon receptors together. The glucagon component accelerates fat breakdown and resting metabolic rate in ways single and dual agonists cannot match, which explains why Phase 3 trials showed an additional 3–4 percentage points of weight loss over Mounjaro.
Weight Loss Results: The Core Numbers
These are trial averages. Individual results vary significantly based on starting weight, diet, exercise habits, and metabolic factors. Roughly 20–30% of users are considered "low responders" on any of these medications.
Speed to results also differs. Most patients see meaningful changes within 8–12 weeks on Mounjaro or Foundayo, while Wegovy and Ozempic typically show noticeable results at the 12–16 week mark due to slower dose escalation protocols.
Cost Breakdown: What You'll Actually Pay in 2026
Insurance is the biggest wildcard. As of early 2026, most commercial insurance plans cover Ozempic for diabetes patients but remain inconsistent on obesity coverage for Wegovy, Mounjaro/Zepbound, and Foundayo. Medicare Part D still excludes weight-loss-only indications under current law, though proposed 2026 legislation may change this.
Compounded semaglutide (the generic equivalent of Ozempic/Wegovy) was legal from FDA-licensed compounding pharmacies through late 2025 but faced renewed restrictions in 2026 as Novo Nordisk resolved its shortage designation. Check current FDA guidance before pursuing this route.
Side Effects: Honest Comparison
All four drugs share a family of GI side effects — nausea, vomiting, diarrhea, and constipation — that are most pronounced during dose escalation and tend to diminish over weeks.
- Nausea usually peaks in first 4–8 weeks, then fades
- Slow titration protocols reduce severity on all four drugs
- GI side effects can be managed with diet changes (smaller meals, low-fat foods)
- Long-term cardiovascular benefits confirmed for semaglutide and tirzepatide
- 5–10% of users discontinue due to GI intolerance
- Muscle mass loss is a concern without resistance training (all four)
- Rare risk of pancreatitis — avoid if personal/family history of pancreatitis
- Foundayo: glucagon component may cause more fatigue and mild increase in heart rate during early weeks
- No long-term safety data beyond 3 years for any of these drugs
Foundayo-specific note: The triple-receptor mechanism introduces a glucagon-mediated metabolic effect that some users experience as increased energy expenditure (a positive) but also as mild fatigue or elevated resting heart rate, particularly in weeks 2–6. This typically resolves. Clinical trials showed no increase in serious cardiovascular events, but post-market monitoring is ongoing.
Insurance Coverage & Prescribing in 2026
- Ozempic: widely covered for Type 2 diabetes; off-label weight use often denied
- Wegovy: coverage improving — about 60% of employer plans now include it
- Mounjaro (Zepbound): similar to Wegovy, depends on plan and BMI documentation
- Foundayo: in formulary review at major PBMs; expect 6–12 months before broad coverage
- Prior authorization required for all four in most plans
- BMI ≥30, or ≥27 with comorbidity, is the standard eligibility threshold
Patients switching from one drug to another (e.g., moving from Wegovy to Mounjaro after a plateau) often face a new round of prior authorization. Document your clinical history and weight trajectory carefully — this supports appeals.
Which Drug Is Right for You?
The answer depends on what you're prioritizing:
Choose Ozempic if you have Type 2 diabetes and your doctor wants an established drug with the longest real-world data. Lowest cost when insurance covers it for diabetes.
Choose Wegovy if you want an FDA-approved weight-loss drug with semaglutide's proven cardiovascular benefits (the SELECT trial showed a 20% reduction in major cardiovascular events). Better insurance coverage than Mounjaro in many plans.
Choose Mounjaro/Zepbound if you've plateaued on semaglutide or want the strongest proven weight-loss results among drugs with 3+ years of real-world safety data. The dual GIP/GLP-1 action genuinely outperforms Wegovy for most patients.
Choose Foundayo if you've tried semaglutide or tirzepatide without reaching goal weight, you're willing to be an early adopter, and cost/coverage isn't a barrier. The additional 3–4% weight loss over Mounjaro is clinically meaningful for patients with severe obesity, but the drug is new and long-term data is still accumulating.
- 3+ years real-world data
- ~21% average weight loss
- Broader insurance coverage
- $1,060/mo list
- FDA approved April 2026
- ~24% average weight loss in trials
- Limited insurance coverage yet
- ~$1,200/mo list
The Bottom Line
Foundayo's approval marks the third wave of GLP-1 innovation, but "newest" doesn't automatically mean "best for everyone." Mounjaro remains the gold standard for proven dual-receptor performance. Wegovy holds the strongest cardiovascular evidence. Ozempic remains the most accessible for diabetic patients with insurance.
If you're starting fresh in 2026, most obesity medicine specialists will likely start you on Wegovy or Mounjaro depending on your insurance — and reserve Foundayo for patients who need that extra clinical push. Discuss your metabolic profile, cardiovascular history, and budget honestly with your prescriber. These drugs work. The question is simply which one works best for your specific situation.
